Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?
BJU International · 2026
DOI: 10.1111/bju.70168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJU International, 2026. Verfasst von Rocco Simone Flammia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Cytoreduction Surgical Procedures, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune‐checkpoint inhibitors (ICIs).
Methods
A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025.
Results
After the screening process, 12 retrospective studies comparing outcomes in patients with mRCC treated with ICI‐based regimens, with or without CN (either upfront or deferred) were deemed eligible. Of those, six indicated a survival benefit for patients undergoing CN in combination with ICIs with hazards ratios ranging from 0.19 to 0.63, a finding that remains consistent within the upfront CN subgroup. However, the included studies’ retrospective nature, inherent selection, and immortal time biases limit definitive conclusions. Ongoing phase III randomised trials, NORDIC‐SUN (ClinicalTrials.gov identifier: NCT03977571) and Southwest Oncology Group (SWOG)‐1931 (also known as PROBE; NCT04510597 ), are evaluating the role of deferred CN after initial ICI therapy, while the role of upfront CN in the ICI era will be likely elucidated by SEVURO‐CN (NCT05753839) trial.
Conclusion
Our findings highlight reconsidering the importance of CN in the ICI era, potentially driven by the influence of tumour burden on anti‐cancer immunity and the limited efficacy of ICIs against primary tumours. Future research, ideally through randomised trials involving patients suitable for safe surgery, should aim to clarify the optimal timing of CN in the context of ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Advanced Surgical Technologies PhD programme, Sapienza University of Rome, Rome, Italy.
- Urological Robotic Surgery and Renal Transplantation Unit, Department of Experimental and Clinical Medicine Careggi Hospital, University of Florence, Florence, Italy.
- European Association of Urology (EAU), Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, The Netherlands.
- Urology Unit, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Verona, Italy.
- Division of Urology, Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
ORCID-Profile: Rocco Simone Flammia, Riccardo Campi
Zitieren
APA
Flammia, R. S., Campi, R., Bologna, E., Bertolo, R., Leonardo, C., Calabrò, F., Amparore, D., Simone, G., & Young Academic Urologists (YAU) Renal Cancer Working Group (2026). Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?. BJU International. https://doi.org/10.1111/bju.70168
Vancouver
Flammia RS, Campi R, Bologna E, Bertolo R, Leonardo C, Calabrò F, et al. Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?. BJU International. 2026. doi:10.1111/bju.70168
BibTeX
@article{Flammia2026,
author = {Flammia, Rocco Simone and Campi, Riccardo and Bologna, Eugenio and Bertolo, Riccardo and Leonardo, Costantino and Calabrò, Fabio and Amparore, Daniele and Simone, Giuseppe and Young Academic Urologists (YAU) Renal Cancer Working Group, Young Academic Urologists (YAU) Renal Cancer Working Group},
title = {Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70168}
}
EUVIMED